Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$220.06 USD
+2.89 (1.33%)
Updated May 17, 2024 04:00 PM ET
After-Market: $220.48 +0.42 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MDGL 220.06 +2.89(1.33%)
Will MDGL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MDGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MDGL
Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals
2 Top Biotech Buyout Candidates
MDGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Akero (AKRO) Slumps 63% on Mixed Results From NASH Study
Other News for MDGL
Paulson & Co's top buy and sells in Q1
John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role
89bio price target lowered by $4 at Evercore ISI, here's why
Akero Therapeutics price target lowered by $12 at Evercore ISI, here's why
Paulson buys Carrols, exits SSR Mining in Q1